|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.855 USD | +11.46% |
|
+73.68% | +213.41% |
| Dec. 07 | Immix Biopharma prices offering of 19.1 million shares at $5.10 per share | RE |
| Nov. 12 | Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer | CI |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Selling General & Admin Expenses, Total | 206K | 1.23M | 4.02M | 7.41M | 11.38M | |
R&D Expenses | 105K | 127K | 4.2M | 8.74M | 11.29M | |
Other Operating Expenses, Total | 311K | 1.35M | 8.22M | 16.14M | 22.67M | |
Operating Income | -311K | -1.35M | -8.22M | -16.14M | -22.67M | |
Interest Expense, Total | -102K | -180K | -497 | - | - | |
Interest And Investment Income | - | - | - | 572K | 1.02M | |
Net Interest Expenses | -102K | -180K | -497 | 572K | 1.02M | |
Other Non Operating Income (Expenses) | -574K | -22.76M | - | - | - | |
EBT, Excl. Unusual Items | -987K | -24.29M | -8.22M | -15.57M | -21.66M | |
Other Unusual Items | - | -86.17K | - | - | - | |
EBT, Incl. Unusual Items | -987K | -24.38M | -8.22M | -15.57M | -21.66M | |
Income Tax Expense | 17.55K | 6.01K | 10.27K | 26.42K | 41.04K | |
Earnings From Continuing Operations | -1M | -24.38M | -8.23M | -15.6M | -21.7M | |
Net Income to Company | -1M | -24.38M | -8.23M | -15.6M | -21.7M | |
Minority Interest | - | - | - | 169K | 84.99K | |
Net Income - (IS) | -1M | -24.38M | -8.23M | -15.43M | -21.61M | |
Net Income to Common Incl Extra Items | -1M | -24.38M | -8.23M | -15.43M | -21.61M | |
Net Income to Common Excl. Extra Items | -1M | -24.38M | -8.23M | -15.43M | -21.61M | |
Per Share Items | ||||||
Net EPS - Basic | -0.3 | -6.64 | -0.59 | -0.89 | -0.76 | |
Basic EPS - Continuing Operations | -0.3 | -6.64 | -0.59 | -0.89 | -0.76 | |
Basic Weighted Average Shares Outstanding | 3.38M | 3.67M | 13.89M | 17.34M | 28.29M | |
Net EPS - Diluted | -0.3 | -6.64 | -0.59 | -0.89 | -0.76 | |
Diluted EPS - Continuing Operations | -0.3 | -6.64 | -0.59 | -0.89 | -0.76 | |
Diluted Weighted Average Shares Outstanding | 3.38M | 3.67M | 13.89M | 17.34M | 28.29M | |
Normalized Basic EPS | -0.18 | -4.13 | -0.37 | -0.55 | -0.48 | |
Normalized Diluted EPS | -0.18 | -4.13 | -0.37 | -0.55 | -0.48 | |
Supplemental Items | ||||||
EBITDA | -308K | -1.35M | -8.22M | -16.14M | -22.64M | |
EBITA | -311K | -1.35M | -8.22M | -16.14M | -22.67M | |
EBIT | -311K | -1.35M | -8.22M | -16.14M | -22.67M | |
EBITDAR | - | - | - | - | -22.42M | |
Effective Tax Rate - (Ratio) | -1.78 | -0.02 | -0.12 | -0.17 | -0.19 | |
Normalized Net Income | -617K | -15.18M | -5.14M | -9.56M | -13.45M | |
Interest on Long-Term Debt | 101K | 120K | 497 | - | - | |
Supplemental Operating Expense Items | ||||||
General and Administrative Expenses | 206K | 1.23M | 4.02M | 7.41M | 11.16M | |
Research And Development Expense From Footnotes | 105K | 127K | 4.2M | 8.74M | 11.29M | |
Net Rental Expense, Total | - | - | - | - | 225K | |
Stock-Based Comp., G&A Exp. (Total) | - | - | 524K | 2.57M | 1.84M | |
Stock-Based Comp., Other (Total) | - | 219K | 100K | - | 1.18M | |
Total Stock-Based Compensation | - | 219K | 624K | 2.57M | 3.02M |
- Stock Market
- Equities
- IMMX Stock
- Financials Immix Biopharma, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
